EHA 2017 | Navigating advances in the myeloma landscape over the past couple of years
Saad Usmani
• 22 Jun 2017
Saad Usmani, MD, FACP, from the Levine Cancer Institute, Charlotte, NC, USA, summarises the developments in drug and mechanisms of actions developed in myeloma over the past two years. He also talks about newer immunotherapies that are being developed, targeting not simply the myeloma cells, but also the checkpoint inhibition pathway, as well as the bone marrow micro-environment. There is a lot of data being generated within the immunotherapy umbrella, ranging from monoclonal antibodies, antibody drug conjugates, BCMA-specific CAR-T cell therapies, and specific by-specific T-cell engagers. Recorded at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
